Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines
Authors
Keywords
-
Journal
PEDIATRIC RESEARCH
Volume 79, Issue 3, Pages 371-377
Publisher
Springer Nature
Online
2015-11-24
DOI
10.1038/pr.2015.246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
- (2015) Danielle M. Lussier et al. JOURNAL OF IMMUNOTHERAPY
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization
- (2015) B. T. Rekoske et al. Cancer Immunology Research
- Nivolumab in NSCLC: latest evidence and clinical potential
- (2015) Raghav Sundar et al. Therapeutic Advances in Medical Oncology
- CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study
- (2015) Benedikt Fritzsching et al. OncoImmunology
- Childhood and adolescent cancer statistics, 2014
- (2014) Elizabeth Ward et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Children's Oncology Group Childhood Cancer Research Network (CCRN): Case catchment in the United States
- (2014) Jessica R. B. Musselman et al. CANCER
- Declining childhood and adolescent cancer mortality
- (2014) Malcolm A. Smith et al. CANCER
- Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
- (2014) L. Karyampudi et al. CANCER RESEARCH
- Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors
- (2014) J. Fu et al. CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immune-based therapies for childhood cancer
- (2014) Crystal L. Mackall et al. Nature Reviews Clinical Oncology
- The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer
- (2014) Laura S. van Dam et al. PEDIATRIC BLOOD & CANCER
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
- (2014) L.B. Jilaveanu et al. Journal of Cancer
- Programmed Cell Death Ligand 1 Expression in Osteosarcoma
- (2014) J. K. Shen et al. Cancer Immunology Research
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
- (2013) Jung Ryul Kim et al. PLoS One
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients
- (2011) Steven E. Finkelstein et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Risk of recurrence and survival after relapse in patients with Ewing sarcoma
- (2011) Martin Stahl et al. PEDIATRIC BLOOD & CANCER
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Clinical significance of B7-H1(PD-L1)expression in human acute leukemia
- (2010) Xiangli Chen et al. CANCER BIOLOGY & THERAPY
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study
- (2009) Linda Granowetter et al. JOURNAL OF CLINICAL ONCOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients
- (2008) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started